Future of Medtech: Define New Markets Before They Define You
Medtech companies willing to do business in new ways and develop holistic approaches to meet their customers’ needs stand to exceed industry growth forecasts and reap significant revenue rewards. To achieve this growth, medtech companies must move beyond the traditional playbook of incremental product improvements, narrow M&A activity and investment in sales and marketing efforts. This report from PwC – an associate member of AdvaMed® – presents three growth strategies to win in this competitive and rapidly changing environment. Each medtech company’s path to growth can draw from any or all of these strategies. The most successful will find the right blend of the three.
Related Reading
News / Business Development
AdvaMed Welcomes Formation of New Medtech Company Targeting Gastrointestinal Treatments
July 25, 2025
WASHINGTON, D.C.—Scott Whitaker, president and CEO of AdvaMed, the medtech association, made the following comment on the collaboration between Revival Healthcare Capital and Olympus Corporation to co-found Swan EndoSurgical, Inc. to develop a robotics platform to provide earlier, safer, and more effective treatment of lesions or tumors in the gastrointestinal tract relative to current therapeutic options.
News / Business Development / Government & Legislative Affairs / Small Business
AdvaMed Welcomes Introduction of American Innovation and Jobs Act
May 22, 2025
WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.
Resource / Business Development / Digital Health / Supply Chain
Accelerating Healthcare Solutions with B2B eCommerce
April 7, 2025
EPAM recently published a case study highlighting the rise of composable commerce solutions to enable B2B processes in the healthcare industry. This piece focuses on the experience of diagnostics company, Cepheid – a part of Danaher Corporation.
Blog / Coverage & Payment / Diagnostics / Global & Trade / Government & Legislative Affairs / Regulatory Affairs / Small Business
AdvaMed®’s Medical Innovation Agenda for the 119th Congress
March 28, 2025
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Resource / Coverage & Payment / Diagnostics / Global & Trade / Government & Legislative Affairs / Health Access / Legal / Regulatory Affairs / Small Business
The Medical Innovation Agenda for the 119th Congress
March 13, 2025
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Resource / Business Development
Accelerated access to novel cancer therapies at Moores Cancer Center
November 27, 2024
Learn how the EY Clinical Trial Fast Lane solution helps jumpstart clinical trials in 45 to 60 working days through rapid performance of functional services, deep understanding of clinical trial operations, and more.
News / Government & Legislative Affairs / Small Business
AdvaMed® Statement on House Passage of Critical R&D Tax Provision
January 31, 2024
AdvaMed®, the Medtech Association, released the following statement from President and CEO Scott Whitaker upon the passage of a research and development expensing tax provision critical to medtech innovation in the House of Representatives.
News / Business Development / Government & Legislative Affairs
AdvaMed® Urges Congress to Pass R&D Tax Provision Promoting, Preserving Medtech Innovation
January 24, 2024
Scott Whitaker, president and CEO of AdvaMed®, the Medtech Association, today urged Congress to enact a research and development expensing tax provision critical to medtech innovation. The provision would delay a change requiring businesses to deduct their research and development expenses over five years, allowing immediate deduction.